Cenix signs research agreement with Regulus Therapeutics

Cenix will apply its expertise in combining high throughput applications of small RNA-based gene silencing with high content phenotypic analyses in cultured human cells.

The company will thereby screen libraries of synthetic miRNA modulators designed and produced by Regulus, using multi-parametric assays to identify novel lead molecules offering highest therapeutic potential in the area of immunology and inflammation.

Peter Linsley, CSO of Regulus, said: “Regulus is committed to discovering and developing novel microRNA-targeted therapeutics and adding to a large and growing body of knowledge on how individual microRNAs function within the cell. We look forward to working collaboratively with Cenix to identify interesting microRNA-targeted drug candidates.”